Sector: MedicalBIO (NYSE: BIO)
Ranking History
Scan Date: | 11/17/2009 |
Sector: | Medical |
Funamental : | 108 |
Technical : | 228 |
Performance : | 87 |
Overall: | 140 |
Number of Stocks: | 307 |
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 109 |
Technical : | 216 |
Performance : | 112 |
Overall: | 150 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 98 |
Technical : | 188 |
Performance : | 120 |
Overall: | 127 |
Number of Stocks: | 306 |
Headlines
- Trading Outlook for Vermillion Inc. Issued by StockPreacher.com
Nov 16, 2009 06:52 AM | ABT, BIO, CRA
- Bio-Rad Signs Agreement to Acquire Certain Diagnostics Businesses of Biotest AG
Oct 23, 2009 08:28 AM | BIO
- Sundia Appoints Charles D. Maher as Senior Vice President of Sales and Marketing
Oct 15, 2009 08:20 AM | BIO
- Bio-Rad to Report Third-Quarter 2009 Financial Results Tuesday, November 3, 2009
Oct 12, 2009 09:01 AM | BIO
- StockPreacher.com Issues Cautious Trading Outlook for China Medical Technologies Inc.
Sep 16, 2009 06:52 AM | BIO, CMED, IMA, QDEL, VIVO
- BioInformatics, LLC New Report - New Media Marketing Channels: Creating Effective Online Life Science Promotional Videos
Sep 10, 2009 12:42 PM | A, BIO, TMO, WAT
- Bio-Rad Helps Raise $1.1 Million in Napa Valley Tour de Cure
Aug 31, 2009 09:01 AM | BIO
- Poland's Bioton Board To Discuss Organizational Changes Thursday
Mar 05, 2008 02:21 AM | BIO
- Polish Bioton Swings Into 4Q Loss On Revaluation,Forex Losses
Mar 01, 2008 05:33 AM | BIO
- Polish Bioton 3Q Net -27% To PLN10.3M; Beats Forecasts
Nov 14, 2007 02:14 AM | BIO
- Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 11 Percent
Nov 03, 2009 04:56 PM | BIO, BRKR
- Bio-Rad Reports Second-Quarter Currency-Neutral Revenue Growth of 3.5 Percent
Aug 04, 2009 04:53 PM | BIO
- BioAlliance Pharma submits clinical trial new drug application and announces results of its July 27th 2009 General Assembly Meeting
Jul 28, 2009 03:05 PM | BIO
- BioAlliance Pharma SA: Turnover for Q2 2009: Sustained Sales Growth and an NDA for Loramyc® in the USA
Jul 22, 2009 12:36 PM | BIO
- BioAlliance Pharma Signs a Co-Promotion Agreement with Lundbeck for in-Hospital Prescription of the Antidepressant Seroplex®
Jul 21, 2009 12:02 PM | BIO
- Sysmex America Debuts High-end Sample Management System During AACC
Jul 20, 2009 12:06 PM | BIO
- Bio-Rad to Report Second-Quarter 2009 Financial Results Tuesday, August 4, 2009
Jul 13, 2009 09:01 AM | BIO
- BioAlliance Pharma Obtains European Approval for Loramyc® Tablet Embossing and Extension of Its Shelf Life to 36 Months
Jul 09, 2009 12:04 PM | BIO
- Bioalliance Pharma Submits Loramyc® NDA to US FDA And Announces a General Shareholders’ Meeting to Amend Its By-Laws
Jun 15, 2009 01:01 PM | BIO
- Bio-Rad Receives FDA Clearance for ToRC IgG and HSV-1 & HSV-2 IgG Kits on the BioPlex 2200 Multiplex System
Jun 01, 2009 08:32 AM | BIO
- Form 4 BIO RAD LABORATORIES For: Nov 12 Filed by: CRUTCHFIELD BRADFORD (10K)
Nov 13, 2009 07:01 PM
- Form 4 BIO RAD LABORATORIES For: Aug 04 Filed by: TSINGOS CHRISTINE A (10K)
Aug 05, 2009 07:26 PM
- Form 4 BIO RAD LABORATORIES For: Jun 12 Filed by: HUTTON RONALD W (10K)
Jun 16, 2009 06:19 PM
- Form 4 BIO RAD LABORATORIES For: Jun 12 Filed by: WADLER SANFORD (10K)
Jun 16, 2009 06:14 PM
- Form 4 BIO RAD LABORATORIES For: Jun 12 Filed by: Magni Giovanni (10K)
Jun 16, 2009 06:08 PM
- Form 4 BIO RAD LABORATORIES For: Jun 12 Filed by: STARK JAMES R (10K)
Jun 16, 2009 06:00 PM
- Form 4 BIO RAD LABORATORIES For: Mar 25 Filed by: SCHWARTZ ALICE N (10K)
Jun 12, 2009 06:20 PM
- Form 4 SCHWARTZ NORMAN D For: Jun 10 (10K)
Jun 12, 2009 05:39 PM
- Form 4 BIO RAD LABORATORIES For: Jun 10 Filed by: STARK JAMES R (10K)
Jun 12, 2009 05:33 PM
- Form 4 BIO RAD LABORATORIES For: Jun 10 Filed by: GOETZ JOHN (10K)
Jun 12, 2009 05:28 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
BIO
|
Compare to S&P
|
| YTD |
29.50 %
|
7.18 %
|
| 4 Weeks |
6.60 %
|
5.45 %
|
| 12 Weeks |
12.75 %
|
6.30 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 0.73 %
|
|
EPS Growth in Last Year: 36.63 %
|
|
Sales Growth in Last Quarter: 7.93 %
|
|
Sales Growth in Last Quarter: 4.35 %
|
|
